This article is more than 5 years old. Information may no longer be current.

Quarterly net revenue increases to $2.4 million for Alimera

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported $2.4 million in net revenue in the third quarter, a 211% increase from $760,000 in the third quarter of the previous year, according to a press release.

The company attributed the increase to higher use of Iluvien (fluocinolone acetonide intravitreal implant) in Germany and the United Kingdom.

GAAP net loss totaled $7 million, compared with $1.1 million a year ago. GAAP loss per share was $0.17 per share, compared with $0.04 a year ago.

GAAP cost of goods sold increased approximately 517%, totaling $370,000 compared with $60,000 in the third quarter 2013.

The company expects to begin delivery of Iluvien to retina specialist in the U.S. in the first quarter of 2015.